

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

**ESMO
PRECEPTORSHIP**

**SINGAPORE
30 NOV-1 DEC 2022**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Chairs:

Victoria G. Atkinson, Australia

Andrew Furness, United Kingdom

ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

30 November -1 December 2022
Singapore

CO-CHAIRS:

Victoria G. Atkinson, Australia
Andrew Furness, United Kingdom

SPEAKERS:

Carolina Alves Costa Silva, France	Kenneth J. O'Byrne, Australia
Cheng Ean Chee, Singapore	Solange Peters, Switzerland
Deborah Enting, United Kingdom	Ines Pires da Silva, Australia
Pier Francesco Ferrucci, Italy	James Reading, United Kingdom
Boon-Cher Goh, Singapore	Sun Young Rha, Korea
Jenny Lee, Australia	Han Chong Toh, Singapore
Soo Chin Lee, Singapore	Wan Zamaniah B. Wan Ishak, Malaysia
Emma Nicholson, United Kingdom	

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their present indication in cancer treatment
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **12 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 30 November 2022

09:00-09:10 10'	Welcome	Victoria G. Atkinson, AU
09:10-10:05 55'	SESSION 1 Introduction	Chair: Andrew Furness, UK
20'	Principles of tumour immunology: Explaining cellular immunity and immune surveillance	James Reading, UK
20'	Principles of cancer immunotherapy	Han Chong Toh, SG
15'	Discussion	Faculty
10:05-12:25 110'	SESSION 2 Clinical issues	Chair: Victoria G. Atkinson, AU
20'	Predictive biomarkers and response	Kenneth J. O'Byrne, AU
20'	Clinical translation and radiological assessment of efficacy	Boon-Cher Goh, SG
15'	Discussion	Faculty
11:00-11:30	Coffee Break	
20'	Immune related toxicities and management	Ines Pires da Silva, AU
20'	Balancing costs and clinical benefit in medical oncology	Solange Peters, CH
15'	Discussion	Faculty
12:25-13:30	Lunch	
13:30-14:45 75'	SESSION 3 Recent advances with ICPI: Results in approved/unapproved indication – part 1	Chair: Victoria G. Atkinson, AU
20'	Non-small cell lung cancer (NSCLC)	Jenny Lee, AU
20'	Upper GI and colorectal	Sun Young Rha, KR
20'	Hepatocellular carcinoma (HCC)	Cheng Ean Chee, SG
15'	Discussion	Faculty
14:45-15:25 40'	SESSION 4 Audience cases	Chair: Andrew Furness, UK
40'	Participants clinical case discussion (4x10')	Faculty
15:25-16:00	Coffee Break	
16:00-17:35 95'	SESSION 5 Recent advances with ICPI: Results in approved/unapproved indication – part 2	Chair: Andrew Furness, UK
20'	Head and neck cancer	Wan Zamaniah B. Wan Ishak, MY
20'	Gynaecological malignancies and breast cancer	Soo Chin Lee, SG
20'	Melanoma advanced and adjuvant	Victoria G. Atkinson, AU
20'	Advanced urinary cancer (renal and bladder)	Deborah Enting, UK
15'	Discussion	Faculty
18:00	Networking Cocktail Reception	

Thursday, 1 December 2022

09:00-10:10 70'	SESSION 6 Audience cases	Chair: Victoria G. Atkinson, AU
70'	Participants clinical case discussion (7x10')	Faculty
10:10-10:40	Coffee Break	
10:40-12:15 95'	SESSION 7 Future of immuno-oncology	Chair: Victoria G. Atkinson, AU
20'	Cellular therapy for solid tumours	Andrew Furness, UK
20'	Cellular therapy for haematological malignancies	Emma Nicholson, UK
20'	Combination therapy: Future directions	Pier Francesco Ferrucci, IT
20'	Immunotherapy and the microbiome: Current use and future directions	Carolina Alves Costa Silva, FR
15'	Discussion	Faculty
12:15-12:20 5'	Closure and farewell	Andrew Furness, UK
12:20-13:20	Lunch	

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion